<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02309255</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-COR REK ID 2013/1885</org_study_id>
    <nct_id>NCT02309255</nct_id>
  </id_info>
  <brief_title>The NOR-COR Study for Coronary Prevention</brief_title>
  <official_title>The NOR-COR (NORwegian CORonary) Study: Identification of CHD Patients With Poor Adherence to Secondary Prevention and Their Perceived Needs for Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vestre Viken Hospital Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Hospital of Vestfold</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Oslo University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kalmar County Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Vestre Viken Hospital Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The NOR-COR study is a cross-sectional, observational study designed to explore a large&#xD;
      number of cardiovascular, inflammatory, genetic, behavioral, and psychosocial factors&#xD;
      (including anxiety, depression, quality of life) in 1369 patients with established coronary&#xD;
      heart disease (CHD) hospitalized in the Sections for Cardiology at the hospitals in Drammen&#xD;
      (n=722) and Vestfold (n=647). Study data from an extensive questionnaire, clinical and&#xD;
      laboratory data, and sputum/saliva for genetic analyses will be collected.&#xD;
&#xD;
      The main overall aim of the NOR-COR study is to develop new strategies to improve secondary&#xD;
      prevention for underserved high risk patient-groups with CHD. The first study phase aims to&#xD;
      collect information necessary to develop empirically based future secondary coronary&#xD;
      prevention interventions. In a genetic sub-project markers associated with CHD and&#xD;
      personality type will be explored.&#xD;
&#xD;
      The study will evaluate current secondary preventive programs and explore the mechanisms that&#xD;
      link behavioral, psychosocial, inflammatory, and genetic factors to poor prognosis. The study&#xD;
      will in short term provide new knowledge potentially useful for increasing participation in&#xD;
      current cardiac rehabilitation/secondary preventive programs. For a longer perspective these&#xD;
      associations may be useful for design of new intervention programs to selected high risk&#xD;
      patient groups whom may be in need of programs with different content and/or of longer&#xD;
      duration than those currently being applied.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiovascular risk factors, lifestyle, and drug adherence</measure>
    <time_frame>Within 2 years after study inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Readmission with a coronary event, acute myocardial infarctrion and cardiovascular mortality</measure>
    <time_frame>Within 5 years after study inclusion</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>The hospital anxiety and depression scale (HADS)</measure>
    <time_frame>Within 2 years after study inclusion</time_frame>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">975</enrollment>
  <condition>Secondary Coronary Prevention</condition>
  <arm_group>
    <arm_group_label>coronary heart disease patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no intervention</intervention_name>
    <arm_group_label>coronary heart disease patients</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Salvia for genetic analyses&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        1365 CHD patients&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        All patients aged 18-80 years with first or recurrent diagnosis or treatments for CHD: a)&#xD;
        acute myocardial infarction [ICD-10; I21], b) coronary artery by-pass graft operation&#xD;
        (CABG), or c) elective or emergency PCI [ICD-10; I25]) have been identified from hospital&#xD;
        patient discharge lists (diagnostic lists) by searching chronologically after last&#xD;
        admission the past three years. In patients with recurrent diagnosis the last event will&#xD;
        define the event.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cognitive impairment that would invalidate assessment including all patients living at&#xD;
             nursing home and psychosis.&#xD;
&#xD;
          -  Short life expectancy (i.e. &lt;1 year) due to terminal heart (NYHA class 4), lung&#xD;
             (chronic obstructive pulmonary disease GOLD 4)-, liver- or kidney disease (chronic&#xD;
             kidney disease stage 5), malignant disease, or other reason.&#xD;
&#xD;
          -  Not able to understand and write the Norwegian language or refuse to give written&#xD;
             informed consent to study participation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vestre Viken HF, Drammen Hospital and The Hospital of Vestfold</name>
      <address>
        <city>Drammen and TÃ¸nsberg</city>
        <state>Buskerud and Vestfold</state>
        <zip>N-3004</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>November 24, 2014</study_first_submitted>
  <study_first_submitted_qc>December 2, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2014</study_first_posted>
  <last_update_submitted>June 12, 2015</last_update_submitted>
  <last_update_submitted_qc>June 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Secondary coronary prevention</keyword>
  <keyword>Psychosocial factors</keyword>
  <keyword>Cardiac rehabilitation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

